Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial Purpose. To evaluate the efficacy and toxicity of the sequential administration of paclitaxel (Taxol®; BristolMyers Squibb; Princeton, NJ), carboplatin (Paraplatin®; Bristol-Myers Squibb), and oral etoposide (VePesid®; Bristol-Myers Squibb) followed by gemcitabine (Gemzar®; Eli Lilly; Indianapolis, IN) and irinotecan (Campostar®; Pfizer Pharmaceuticals; New York, NY) in the first-line treatment of patients with carcinoma of unknown primary site. Read More →